IL194628A0 - Use of escitalopram for improving cognition - Google Patents

Use of escitalopram for improving cognition

Info

Publication number
IL194628A0
IL194628A0 IL194628A IL19462808A IL194628A0 IL 194628 A0 IL194628 A0 IL 194628A0 IL 194628 A IL194628 A IL 194628A IL 19462808 A IL19462808 A IL 19462808A IL 194628 A0 IL194628 A0 IL 194628A0
Authority
IL
Israel
Prior art keywords
escitalopram
improving cognition
cognition
improving
Prior art date
Application number
IL194628A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL194628A0 publication Critical patent/IL194628A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL194628A 2006-05-02 2008-10-07 Use of escitalopram for improving cognition IL194628A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02
PCT/DK2007/050050 WO2007124757A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition

Publications (1)

Publication Number Publication Date
IL194628A0 true IL194628A0 (en) 2009-08-03

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194628A IL194628A0 (en) 2006-05-02 2008-10-07 Use of escitalopram for improving cognition

Country Status (15)

Country Link
EP (1) EP2026793A2 (pt)
JP (1) JP2009535367A (pt)
KR (1) KR20090009820A (pt)
CN (1) CN101426494A (pt)
AR (1) AR060732A1 (pt)
AU (1) AU2007245983A1 (pt)
BR (1) BRPI0710230A2 (pt)
CA (1) CA2651002A1 (pt)
EA (1) EA200870491A1 (pt)
IL (1) IL194628A0 (pt)
MX (1) MX2008013911A (pt)
NO (1) NO20085009L (pt)
TW (1) TW200812993A (pt)
WO (1) WO2007124757A2 (pt)
ZA (1) ZA200808632B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1535616B1 (en) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US8258139B2 (en) * 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
KR102051624B1 (ko) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
SE9803157D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ATE329620T1 (de) * 2000-12-01 2006-07-15 Be Able Llc Verhaltenchemotherapie
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AU2003287919B2 (en) * 2002-12-23 2009-11-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
JP2009511607A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
EA200801081A1 (ru) * 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram

Also Published As

Publication number Publication date
CA2651002A1 (en) 2007-11-08
CN101426494A (zh) 2009-05-06
KR20090009820A (ko) 2009-01-23
AR060732A1 (es) 2008-07-10
TW200812993A (en) 2008-03-16
ZA200808632B (en) 2009-12-30
AU2007245983A1 (en) 2007-11-08
WO2007124757A3 (en) 2008-07-24
JP2009535367A (ja) 2009-10-01
WO2007124757A2 (en) 2007-11-08
EP2026793A2 (en) 2009-02-25
MX2008013911A (es) 2008-11-12
BRPI0710230A2 (pt) 2011-08-02
EA200870491A1 (ru) 2009-04-28
NO20085009L (no) 2008-12-16

Similar Documents

Publication Publication Date Title
IL194628A0 (en) Use of escitalopram for improving cognition
IL202664A (en) Processes for Preparation of 3-Dihlomethyl-1-Methyl-1H-Pyrazole-4-Carbaldehyde and Intermediates
IL196976A0 (en) Use of azabicyclo hexane derivatives
AU311449S (en) Ncs-emg instrument
EP2097307A4 (en) INSTRUMENT
IL197632A0 (en) Use of jam-c binding compounds
GB0705854D0 (en) Methods of construction
IL196606A0 (en) Use of escin
TWI320362B (en) Enhanced imaging of features
IL197966A0 (en) Use of modified cyclosporin
DK2392335T3 (en) Use of 24-norUDCA
EP2022540A4 (en) INSTRUMENT SLIMMING THE JOUES
PL2038260T3 (pl) Stereoselektywna synteza (S)-1-metylo-3-fenylopiperazyny
GB0700179D0 (en) Use of epoxidised compounds
HUP0500947A2 (en) Composition for treatment of paradontosis
PL381142A1 (pl) Sposób otrzymywania glicydolu
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
GB0612370D0 (en) Uses of (S)-clenbuterol
GB0604575D0 (en) Construction of inductive components
PL1886669T3 (pl) Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego
GB2443891B (en) Process for the purification of meloxicam
GB0625602D0 (en) Treatment of sialorrhoea
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines
TWM311768U (en) Improved structure of A-ladder